CB307 Tri-Partite Humabody® Enhances T-Cells Through PSMA-Dependent CD137 (4-1BB) Agonism

Time: 2:30 pm
day: Day One


• CB307 monovalently binds PSMA, CD137 and HSA, to promote tumourspecific T-cell enhancement
• Humabodies have superior tissue penetration relative to standard monoclonal antibodies
• A CB307 mouse surrogate promotes tumour infiltration of CD8+ T-cells in PBMC engrafted mouse models